RT Journal Article
SR Electronic
T1 Identifying patients at risk for myasthenic crisis with hemogram and inflammation-related laboratory parameters – a pilot study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.09.19.23295421
DO 10.1101/2023.09.19.23295421
A1 Mehnert, Anne
A1 Bershan, Sivan
A1 Kollmus-Heege, Jil
A1 Gerischer, Lea
A1 Herdick, Meret Luise
A1 Hoffmann, Sarah
A1 Lehnerer, Sophie
A1 Scheibe, Franziska
A1 Stascheit, Frauke
A1 Stein, Maike
A1 Buchan, Alastair M.
A1 Meisel, Andreas
A1 Aigner, Annette
A1 Mergenthaler, Philipp
YR 2023
UL http://medrxiv.org/content/early/2023/09/20/2023.09.19.23295421.abstract
AB Background Myasthenia gravis (MG) is a rare autoimmune disease characterized by fatigable weakness of the voluntary muscles and can exacerbate to life-threatening myasthenic crisis (MC), requiring intensive care treatment. Routine laboratory parameters are a cost-effective and widely available method for estimating clinical outcomes of several diseases, but so far such parameters have not been established to detect disease progression in MG.Methods We conducted a retrospective analysis of selected laboratory parameters related to inflammation and hemogram for MG patients with MC matched to MG patients without MC. To identify potential risk factors for MC, we applied time-varying Cox regression for time to MC, and as a sensitivity analysis generalized estimating equations logistic regression for the occurrence of MC at the next patient visit.Results 15 of the 58 examined MG patients suffered at least one MC. There was no notable difference in the occurrence of MC by antibody status or sex. Both regression models showed that higher counts of basophils (per 0.01 units increase: HRlJ=lJ1.32, 95% CIlJ=1.02-1.70), neutrophils (per 1 unit increase: HRlJ=lJ1.40, 95% CIlJ=lJ1.14-1.72), and potentially leukocytes (per 1 unit increase: HR = 1.15, 95% CI = 0.99-1.34), and platelets (per 100 units increase: HR = 1.54, 95% CI = 0.99-2.38) may indicate increased risk for a myasthenic crisis.Conclusion This pilot study provides proof of concept that increased counts of basophils, neutrophils, leukocytes, and platelets may be associated with a higher risk for developing MC in patients with MG.Competing Interest StatementS.B. is co-owner of exago.ml, a geoanalytics-focused machine learning company. S.H. has received speaker's honoraria from Alexion, argenx, UCB and Roche and honoraria for attendance at advisory boards from Alexion, argenx and Roche, and is member of the medical advisory board of the German Myasthenia Society. S.L. has received speaker's honoraria from Alexion, argenx, Hormosan and UCB, and honoraria for attendance of advisory boards from Alexion, argenx, Biogen, HUMA, UCB and Roche. F.St. received speaker's honoraria and honoria for attendance of advisory boards from Alexion, argenx and UCB Pharma. M.S. received speaker's honoraria for attendance at patient events from argenx and Alexion. A.M. has received speaker's honoraria, consulting fees or (institutional) financial research support from Alexion Pharmaceuticals Inc., Argenx, Grifols SA, Hormosan Pharma GmbH, Janssen, Octapharma, and UCB Pharma, and is chairman of the medical advisory board of the German Myasthenia Society. P.M. has been on the board of HealthNextGen. All other authors do not report any conflicts of interest.Funding StatementThis study did not receive dedicated funding. P.M. is Einstein Junior Fellow and A.M.B. is Einstein Visiting Fellow both funded by the Einstein Foundation Berlin. P.M. acknowledges funding support by the Einstein Foundation Berlin (EJF-2020-602; EVF-BUA-2022-694), P.M. and A.M.B. acknowledge joint funding by the Einstein Foundation Berlin (EVF-2021-619) and the Leducq Foundation for Cardiovascular and Neurovascular Research (Consortium International pour la Recherche Circadienne sur l'AVC). Besides funding, the sponsoring organizations did not play any role in the design of the study, preparation, review, or approval of the manuscript, or decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Charité - Universitätsmedizin Berlin gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes